ivabradine sold brand name procoralan among others medication pacemaker current inhibitor used symptomatic management heartrelated chest pain heart failure patients qualify use ivabradine coronary heart failure patients symptomatic heart failure reduced ejection volume heart rate least bpm condition able fully managed beta ivabradine acts allowing negative chronotropy sinoatrial structure thus reducing heart rate via specific inhibition pacemaker current mechanism different beta blockers calcium channel blockers two commonly prescribed antianginal classes cardiac pharmaceuticals ivabradine apparent inotropic properties may cardiotonic agent used symptomatic treatment chronic stable angina pectoris patients normal sinus rhythm take beta blockers also used offlabel treatment inappropriate sinus ivabradine stands pharmacological option controlling hr rhythm without associated side effects postoperative cabg patients ivabradine effective beta blocker atenolol comparable amlodipine management chronic stable angina demonstrated improvements total exercise duration noninferiority trials hence alternative therapy tolerate conventional people sufficiently managed beta blockers angina adding ivabradine reduce heart rate improve total exercise used combination beta blockers people heart failure lvef lower percent inadequately controlled beta blockers alone whose heart rate exceeds beats per people sufficiently managed beta blockers heart failure adding ivabradine decreases risk hospitalization heart clinical use ivabradine predicated mechanism action sinoatrial nodal tissue selectively inhibits funny current results decrease heart ivabradine frequent application electrophysiology treatment inappropriate sinus tachycardia use inappropriate sinus tachycardia european medicines agencyfood drug indication used experimentally treatment postural orthostatic tachycardia syndrome patients long ivabradine contraindicated sick sinus syndrome also used concomitantly potent inhibitors including azole antifungals ketoconazole macrolide antibiotics nefazodone antiretroviral drugs nelfinavir use ivabradine verapamil diltiazem overall patients taking ivabradine experience luminous phenomena patients described sensations enhanced brightness fully maintained visual field probably due blockage ih ion channels retina similar cardiac symptoms mild transient fully reversible clinical studies patients discontinue drug sensations occurred average days drug large clinical trial bradycardia unusually slow heart rate occurred patients taking ivabradine doses mg respectively compared taking reported common adverse drug reactions patients include firstdegree av block ventricular extrasystoles dizziness andor blurred ivabradine acts f funny called unusual properties compared current systems known time discovery ion current highly expressed sinoatrial node mixed inward current activated hyperpolarization modulated autonomic nervous system one important ionic currents regulating pacemaker activity sinoatrial sa node ivabradine selectively inhibits pacemaker current dosedependent manner blocking channel reduces cardiac pacemaker activity selectively slowing heart rate allowing time blood flow inhibiting channel ivabradine reduces heart rate workload heart relevant usage medication treat angina well congestive heart failure contrast commonly used ratereducing medications betablockers calcium channel blockers reduce heart rate also cardiac contractility given selective decrease rate without loss contractility ivabradine may prove efficacious treatment congestive heart failure reduced ejection fraction ivabradine binds receptors potassiumsodium hyperpolarizationactivated cyclic nucleotidegated channel utilizing beautiful study randomised patients stable coronary artery disease left ventricle dysfunction ejection fraction ivabradine show significant reduction primary composite endpoint cardiovascular death admission hospital acute myocardial infarction admission hospital new onset worsening heart failure however prespecified subgroup patients baseline heart rate bpm ivabradine significantly reduced following secondary results seen combination therapy beta blockers found safe effective improving coronary artery disease outcomes patients heart rates bpm signify trial randomised patients stable coronary artery disease elevated heart rate greater beats per minute assigned intervention ivabradine placebo addition standard therapy ivabradine significantly improve secondary outcomes patient groups however demonstrate reduction heart rate compared shift study reduction cardiovascular death hospital admission also demonstrated hence considered additional therapy shift study ivabradine significantly reduced risk primary composite endpoint hospitalization worsening heart failure cardiovascular death compared placebo top optimal benefits observed months treatment shift also showed administration ivabradine heart failure patients significantly reduced risk death heart failure hospitalization heart failure improvements outcomes observed throughout prespecified subgroups female male without betablockers randomization patients years age heart failure ischemic nonischemic etiology nyha class ii class iii iv without diabetes without cochrane review found difference cardiovascular mortality serious adverse events longterm treatment ivabradine placebousual careno treatment participants heart failure reduced ejection note caution must emphasised ivabradine though indicated chronic heart failure patients clinically stable indicated acute heart failure enhanced heart rate represents cardiac reserve indiscriminate use ivabradine could destabilise patients ivabradine approved european medicines agency united states food drug administration marketed amgen trade name corlanor united servier rest world trade names procoralan worldwide coralan hong kong singapore australia countries corlentor armenia spain italy romania lancora canada coraxan russia serbia also marketed india brand names ivabrad ivabid iran sold trademark bradix ivamac bradia development ivabradine known httpsenwikipediaorgwikiivabradine